Last reviewed · How we verify
NCT04207775: PISCES
Real World Study in Locally Advanced or Metastatic NSCLC Patients, Progressed From First-line EGFR-TKI Therapy
trial in Locally Advanced or Metastatic NSCLC in 300 participants. Completed in 1 September 2023.
1 September 2023
Quick facts
| Lead sponsor | AstraZeneca |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 30 March 2020 |
| Primary completion | 1 September 2023 |
| Estimated completion | 1 September 2023 |
| Sites | 16 locations across China |
Conditions studied
- Locally Advanced or Metastatic NSCLC — all drugs for Locally Advanced or Metastatic NSCLC →
Sponsor
AstraZeneca — full company profile →
Who can join
18 and older, any sex, with Locally Advanced or Metastatic NSCLC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To estimate parameters associated with treatment patterns and related clinical outcomes.Including physician reported PFS and OS.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Molecular testing, treatment patterns, and outcomes in EGFR-mutated non-small cell lung cancer: the PISCES study.
Tian P, Wu L, Zhou C, Tan J, et al · · 2025 · cited 1× · PMID 40717496 · DOI 10.1080/14796694.2025.2529094
Verify or expand the search:
- PubMed search for NCT04207775
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Locally Advanced or Metastatic NSCLC
Currently open trials in the same condition.
- NCT06461156 — A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC) · Phase 1 · recruiting
- NCT04143607 — ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC · Phase 3 · active not recruiting
- NCT03969823 — Whole Genomic Landscape of Advanced EGFR-mutant NSCLC · NA · active not recruiting
Other AstraZeneca trials
Trials by the same sponsor.
- NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
- NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
- NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
- NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
- NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04207775 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
- Last refreshed: 12 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04207775.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing